December 2025
1. MOON S, Hong S, Han K, Park CY, et al
   Effects of cilostazol on the prognosis of lower extremity peripheral arterial disease in patients with diabetes mellitus in Korea: A nationwide population-based study.
   Atherosclerosis. 2025;413:120634.
   

   >> Share

   
   October 2025
2. ARNOLD N, Gossling A, Weimann J, Bay B, et al
   Occurrence of coronary events in the absence of traditional risk factors: Understanding residual risk.
   Atherosclerosis. 2025;409:120475.
   

   >> Share

   
   August 2025
3. WANG Y, Yang K, Jiang G, Zheng X, et al
   Twist1 promoting neointima hyperplasia after vascular injury in diabetes via regulating hyperglycemia-induced phenotype switching of vascular smooth muscle cells.
   Atherosclerosis. 2025;409:120496.
   

   >> Share

   
   
4. KITAHARA S, Kataoka Y, Nicholls SJ, Funabashi S, et al
   Apolipoprotein CIII in statin-treated type 2 diabetic patients: Its implications for plaque progression and instability: The pre-specified analysis from the OPTIMAL randomized controlled trial.
   Atherosclerosis. 2025;409:120470.
   

   >> Share

   
   July 2025
5. HE D, Li C, Yang C, Wang J, et al
   Difference between cystatin C- and creatinine-based estimated glomerular filtration rate, diabetes status, and incident peripheral artery disease: A population-based cohort study.
   Atherosclerosis. 2025;408:120452.
   

   >> Share

   
   
6. SVENDSEN K, Christensen JJ, Igland J, Krogh HW, et al
   Risk of adverse pregnancy outcomes and impact of statin use in pregnant women with familial hypercholesterolemia.
   Atherosclerosis. 2025;408:120442.
   

   >> Share

   
   June 2025
7. CAO BF, Liu K, Chen HW, Xu ZY, et al
   Impact of baseline and trajectory of the cardiometabolic indices on incident microvascular complications in patients with type 2 diabetes.
   Atherosclerosis. 2025;407:120407.
   

   >> Share

   
   March 2025
8. RIKHI R, Haidar A, Bhatia HS, Beam K, et al
   Association of lipoprotein(a) and diabetes in primary prevention of coronary heart disease: The Multi-Ethnic Study of Atherosclerosis (MESA).
   Atherosclerosis. 2025;404:119179.
   

   >> Share

   
   February 2025
9. KRUGER A, Willems van Dijk K, van Heemst D, Noordam R, et al
   Long-term body mass index trajectories and the risk of type 2 diabetes mellitus and atherosclerotic cardiovascular disease using healthcare data from UK Biobank participants.
   Atherosclerosis. 2025;403:119135.
   

   >> Share

   
   January 2025
10. SUN M, Lu Z, Chen WM, Lv S, et al
    N-acetylcysteine therapy reduces major adverse cardiovascular events in patients with type 2 diabetes mellitus.
    Atherosclerosis. 2025;402:119117.
    

    >> Share

    
    
11. MUELLER M, Charwat-Resl S, Schulze-Bauer HS, Nguyen C, et al
    Vascular strain of the aorta and peripheral arteries in patients with type 1 diabetes mellitus in comparison with healthy controls.
    Atherosclerosis. 2025;402:119106.
    

    >> Share

    
    October 2024
12. JIMENEZ-SANCHEZ C, Oberhauser L, Maechler P
    Role of fatty acids in the pathogenesis of ss-cell failure and Type-2 diabetes.
    Atherosclerosis. 2024 Oct 4:118623. doi: 10.1016/j.atherosclerosis.2024.118623.
    

    >> Share

    
    September 2024
13. UNGER E, Makarova N, Borof K, Schlieker P, et al
    Association of adverse pregnancy outcomes with cardiovascular risk profiles in later life: Current insights from the Hamburg City Health Study (HCHS).
    Atherosclerosis. 2024;396:118526.
    

    >> Share

    
    August 2024
14. CHEN JX, Lu Q, Geng T, Wang Y, et al
    Differences in HDL-related coronary heart disease risk between individuals with and without diabetes.
    Atherosclerosis. 2024;397:118553.
    

    >> Share

    
    
15. LIU WX, Hu YF, Tai GJ, Li YP, et al
    Macrophages regulate plaque progression in diabetic Apoe(-/-) mice dependent on Pi4p/Nlrp3 signaling pathway.
    Atherosclerosis. 2024;397:118556.
    

    >> Share

    
    
16. GROENEN AG, Halmos B, van Zeventer IA, Salzbrunn JB, et al
    Skin autofluorescence, a measure for accumulation of advanced glycation end products, positively associates with blood neutrophil and monocyte counts in the general population, and particularly in men with prediabetes.
    Atherosclerosis. 2024;395:117609.
    

    >> Share

    
    July 2024
17. AJAY AK, Zhu LJ, Zhao L, Liu Q, et al
    Local vascular Klotho mediates diabetes-induced atherosclerosis via ERK1/2 and PI3-kinase-dependent signaling pathways.
    Atherosclerosis. 2024;396:118531.
    

    >> Share

    
    
18. WESTCOTT F, Dearlove DJ, Hodson L
    Hepatic fatty acid and glucose handling in metabolic disease: Potential impact on cardiovascular disease risk.
    Atherosclerosis. 2024;394:117237.
    

    >> Share

    
    
19. BECHMANN LE, Emanuelsson F, Nordestgaard BG, Benn M, et al
    SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type.
    Atherosclerosis. 2024;394:117236.
    

    >> Share

    
    June 2024
20. GAGNON E, Bourgault J, Gobeil E, Theriault S, et al
    Impact of loss-of-function in angiopoietin-like 4 on the human phenome.
    Atherosclerosis. 2024;393:117558.
    

    >> Share

    
    May 2024
21. BOREN J, Oorni K, Catapano AL
    The link between diabetes and cardiovascular disease.
    Atherosclerosis. 2024 May 29:117607. doi: 10.1016/j.atherosclerosis.2024.117607.
    

    >> Share

    
    
22. ROSENSON RS, Tate A, Mar P, Grushko O, et al
    Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects.
    Atherosclerosis. 2024;392:117529.
    

    >> Share

    
    April 2024
23. DARDANO A, Bianchi C, Garofolo M, Del Prato S, et al
    The current landscape for diabetes treatment: Preventing diabetes-associated CV risk.
    Atherosclerosis. 2024 Apr 23:117560. doi: 10.1016/j.atherosclerosis.2024.117560.
    

    >> Share

    
    
24. LUCIANI L, Pedrelli M, Parini P
    Modification of lipoprotein metabolism and function driving atherogenesis in diabetes.
    Atherosclerosis. 2024 Apr 17:117545. doi: 10.1016/j.atherosclerosis.2024.117545.
    

    >> Share

    
    
25. ARSENAULT BJ, Carpentier AC, Poirier P, Despres JP, et al
    Adiposity, type 2 diabetes and atherosclerotic cardiovascular disease risk: Use and abuse of the body mass index.
    Atherosclerosis. 2024 Apr 14:117546. doi: 10.1016/j.atherosclerosis.2024.117546.
    

    >> Share

    
    March 2024
26. DING X, Qiu Y, Wu G, Li S, et al
    l-thyroxine attenuates extracellular Hsp90alpha-induced vascular endothelial calcification in diabetes mellitus, as revealed by parallel metabolic profiles.
    Atherosclerosis. 2024;392:117527.
    

    >> Share

    
    
27. VARGAS-VAZQUEZ A, Fermin-Martinez CA, Antonio-Villa NE, Fernandez-Chirino L, et al
    Insulin resistance potentiates the effect of remnant cholesterol on cardiovascular mortality in individuals without diabetes.
    Atherosclerosis. 2024 Mar 13:117508. doi: 10.1016/j.atherosclerosis.2024.117508.
    

    >> Share

    
    February 2024
28. KIM H, Choi CU, Rhew K, Park J, et al
    Comparative effects of glucose-lowering agents on endothelial function and arterial stiffness in patients with type 2 diabetes: A network meta-analysis.
    Atherosclerosis. 2024;391:117490.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share